Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease

We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease (PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in-vitro gut model. The effects of dosing with an oral probiotic suspens...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonas Ghyselinck (Author), Lynn Verstrepen (Author), Frédéric Moens (Author), Pieter Van Den Abbeele (Author), Arnout Bruggeman (Author), Jawal Said (Author), Barry Smith (Author), Lynne Ann Barker (Author), Caroline Jordan (Author), Valentina Leta (Author), K. Ray Chaudhuri (Author), Abdul W. Basit (Author), Simon Gaisford (Author)
Format: Book
Published: Elsevier, 2021-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_e3aa7d60d1ea4eec9ae8946c46ee25a8
042 |a dc 
100 1 0 |a Jonas Ghyselinck  |e author 
700 1 0 |a Lynn Verstrepen  |e author 
700 1 0 |a Frédéric Moens  |e author 
700 1 0 |a Pieter Van Den Abbeele  |e author 
700 1 0 |a Arnout Bruggeman  |e author 
700 1 0 |a Jawal Said  |e author 
700 1 0 |a Barry Smith  |e author 
700 1 0 |a Lynne Ann Barker  |e author 
700 1 0 |a Caroline Jordan  |e author 
700 1 0 |a Valentina Leta  |e author 
700 1 0 |a K. Ray Chaudhuri  |e author 
700 1 0 |a Abdul W. Basit  |e author 
700 1 0 |a Simon Gaisford  |e author 
245 0 0 |a Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease 
260 |b Elsevier,   |c 2021-12-01T00:00:00Z. 
500 |a 2590-1567 
500 |a 10.1016/j.ijpx.2021.100087 
520 |a We report here the potential role of a 4-strain probiotic suspension for use with patients with Parkinson's disease (PD). Stool samples from a group of three patients with diagnosed PD were used to create microbiotas in an in-vitro gut model. The effects of dosing with an oral probiotic suspension (Symprove) on bacterial composition and metabolic activity in the microbiotas was evaluated over 48 h and compared with healthy controls. Additionally, the effect of probiotic dosing on epithelial tight-junction integrity, production of inflammatory markers and wound healing were evaluated in cell culture models. In general, the relative proportions of the main bacterial phyla in the microbiotas of PD patients differed from those of healthy subjects, with levels of Firmicutes raised and levels of Bacteroidetes reduced. Dosing with probiotic resulted in a change in bacterial composition in the microbiotas over a 48 h period. Several other indicators of gut health changed upon dosing with the probiotic; production of short chain fatty acids (SCFAs) and lactate was stimulated, levels of anti-inflammatory cytokines (IL-6, IL-10) increased and levels of pro-inflammatory cytokines and chemokines (MCP-1 and IL-8) decreased. Tight junction integrity was seen to improve with probiotic dosing and wound healing was seen to occur faster than a control. The data suggest that if development and/or progression of PD is influenced by gut microbiota dysbiosis then supplementation of the diet with a properly formulated probiotic may be a useful adjunct to standard treatment in clinic. 
546 |a EN 
690 |a Probiotics 
690 |a Gastrointestinal microbiome 
690 |a Lactobacillus 
690 |a Parkinson's disease 
690 |a Epithelial gut wall integrity 
690 |a Butyrate 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n International Journal of Pharmaceutics: X, Vol 3, Iss , Pp 100087- (2021) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2590156721000165 
787 0 |n https://doaj.org/toc/2590-1567 
856 4 1 |u https://doaj.org/article/e3aa7d60d1ea4eec9ae8946c46ee25a8  |z Connect to this object online.